Research progress of pyrroline-5-carboxylic acid reductase-1 in malignant tumor

doi:10.3877/cma.j.issn.2095-5820.2020.03.001

Abstract

Abstract:

Pyrroline-5-carboxylate Reductase-1 (PYCR1) is a kind of mitochondrial enzyme, and its gene mutation could lead to human skin relaxation. Recent studies have shown that PYCR1 could promote tumor growth and proliferation by affecting praline metabolism. PYCR1 was highly expressed in several kinds of cancers, and the level of expression of PYCR1 was negatively related to the prognosis of patients.Therefore, PYCR1 may be used as a new marker in the diagnosis and prognosis of tumor, and may become a new target of tumor treatment.

Key words: Pyrroline-5-Carboxylate Reductase-1, Cancer, Progress

Lihong Zhang, Chaochao Wang. Research progress of pyrroline-5-carboxylic acid reductase-1 in malignant tumor[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2020, 08(03): 129-132.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2020.03.001

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2020/V08/I03/129

References 30

[1]	Liang X, Zhang L, Nataraian SK, et al. Proline mechanisms of stress survival [J]. Antioxid Redox Signal, 2013,19(9):998-1011.
[2]	Phang JM, Pandhare J, Liu Y. The metabolism of proline as microenvironmental stress substrate[J]. J Nutr, 2008,138(10):2008S-2015S.
[3]	Meng ZH, Lou Z, Liu Z, et al. Crystal structure of human pyrroline-5-carboxylate reductase[J]. J Mol Biol, 2006,359(5):1364-1377.
[4]	Reversade B, Escande-Beillard N, Dimopoulou A, et al. Mutations in PYCR1 cause cutis laxa with progeroid features[J]. Nat Genet, 2009, 41(9):1016-1021.
[5]	Lin DS, Yeung CY, Liu HL, et al. A novel mutation in PYCR1 causes an autosomal recessive cutis laxa with premature aging features in a family[J]. Am J Med Genet A, 2011,155A(6):1285-1289.
[6]	Scherrer DZ, Baptista MB, Matos AH, et al. Mutations in PYCR1 gene in three families with autosomal recessive cutis laxa, type 2[J]. Eur J Med Genet, 2013,56(6):336-339.
[7]	Kretz R, Bozorgmehr B, Kariminejad MH, et al. Defect in proline synthesis: pyrroline-5-carboxylate reductase 1 deficiency leads to a complex clinical phenotype with collagen and elastin abnormalities[J]. J Inherit Metab Dis, 2011,34(3):731-739.
[8]	Sun T, Song Y, Yu H, et al. Identification of lncRNA TRPM2-AS/miR-140-3p/PYCR1 axis's proliferates and anti-apoptotic effect on breast cancer using co-expression network analysis[J]. Cancer Biol Ther, 2019,20(6):760-773.
[9]	Hollinshead KER, Munford H, Eales KL, et al. Oncogenic IDH1 Mutations Promote Enhanced Proline Synthesis through PYCR1 to Support the Maintenance of Mitochondrial Redox Homeostasis[J]. Cell Rep, 2018,22(12):3107-3114.
[10]	Dimopoulou A, Fischer B, Gardeitchik T, et al. Genotype-phenotype spectrum of PYCR1-related autosomal recessive cutis laxa[J]. Mol Genet Metab, 2013,110(3):352-361.
[11]	Ritelli M, Palit A, Giacopuzzi E, et al. Clinical and molecular characterization of a 13-year-old Indian boy with cutis laxa type 2B: Identification of two novel PYCR1 mutations by amplicon-based semiconductor exome sequencing[J]. J Dermatol Sci, 2017, 88(1):141-143.
[12]	Gardeitchik T, Mohamed M, Fischer B, et al. Clinical and biochemical features guiding the diagnostics in neurometabolic cutis laxa[J]. Eur J Hum Genet, 2014,22(7):888-895.
[13]	Guernsey DL, Jiang H, Evans SC, et al. Mutation in pyrroline-5-carboxylate reductase 1 gene in families with cutis laxa type 2[J]. Am Hum Genet, 2009,85(1):120-129.
[14]	Eduard AS, Erwin EWJ, Gajja SS. Human pyrroline-5-carboxylate reductase (PYCR1) acts on Δ1-piperideine-6-carboxylate generating L-pipecolic acid[J]. J Inherit Metab Dis, 2014, 37(3):327-332.
[15]	Elia I, Broekaert D, Christen S, et al. Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells[J]. Nat Commun, 2017,8:15267.
[16]	Phang JM, Liu W, Hancock CN, et al. Proline metabo-lism and cancer: Emerging links to glutamine and collagen[J]. Curr Opin Clin Nutr Metab Care, 2015,18(1):7177.
[17]	Liu W, Phang JM. Proline dehydrogenase (oxidase) in cancer[J]. Biofactors, 2012,38(6):398406.
[18]	Krishnan N, Dickman MB, Becker DF. Proline modulates the intracellular redox environment and protects mammalian cells against oxidative stress[J]. Free Radic Biol Med, 2008,44(4):671-681.
[19]	Chen SY, Yang X, Yu M, et al. SIRT3 regulates cancer cellproliferation through deacetylation of PYCR1 in proline metabolism[J]. Neoplasia, 2019,21(7):665-675.
[20]	Craze ML, Cheung H, Jewa N, et al. MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer[J]. Br J Cancer, 2018,118(2):258-265.
[21]	Possemato R, Marks KM, Shaul YD, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer[J]. Nature, 2011,476(7360):346-350.
[22]	Ding JF, Kuo ML, Su LL, et al. Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers[J]. Carcinogenesis, 2017,38(5):519-531.
[23]	Cai F, Miao YY, Liu CY, et al. Pyrroline5carboxylate reductase 1 promotes proliferation and inhibits apoptosis in nonsmall cell lung cancer[J]. Oncology Letters, 2018,15(1):731-740.
[24]	Yang SC, Liu Y, Li MY, et al. FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer[J]. Mol Cancer, 2017,16(1):124.
[25]	Wang DC, Wang LC, Zhang Y, et al. PYCR1 promotes the progression of non-small-cell lung cancer under the negative regulation of miR-488[J]. Biomed Pharmacother, 2019,111:588-595.
[26]	Jariwala U, Prescott J, Jia L, et al. Identification of novel androgen receptor target genes in prostate cancer[J]. Mol Cancer, 2007,6:39.
[27]	Ernst T, Hergenhahn M, Kenzelmann M, et al. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue[J]. Am J Pathol, 2002,160(6):2169-2180.
[28]	Zeng T, Zhu L, Liao M, et al. Knockdown of PYCR1 inhibits cell proliferation and colony formation via cell cycle arrest and apoptosis in prostate cancer[J]. Med Oncol, 2017,34(2):27.
[29]	Fu WJ, Xie ZB, Zheng SF, et al. The clinical significance of PYCR1 expression in renal cell carcinoma[J]. Medicine, 2019,98(28):e16384.
[30]	Zhuang JH, Song YN, Ye Y, et al. PYCR1 interference inhibits cell growth and survival via cJun Nterminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer[J]. J Transl Med, 2019,17(1):343.

Please choose a citation manager

Content to export